Phase 3 clinical trial will evaluate aglatimagene besadenovec plus valacyclovir in combination with continued pembrolizumab versus standard-of-care docetaxel chemotherapy in patie ...

The FDA has granted Fast Track designation to BM-3103, a novel topical mTOR inhibitor for epidermolysis bullosa simplex currently in phase 2.

Two Southern California men are among eight people indicted Thursday over an alleged plot to carry out a terrorist attack at ...

SHELTON, CT / ACCESS Newswire / July 6, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical ...

Infamous celebrities Lindsay Lohan and Charlie Sheen seemed to be a perfect pair in "Scary Movie 5." Reportedly, the stars ...

Herpes is one of the most common sexually transmitted infections, yet it's surrounded by confusion and misinformation. Many ...

Innovative Molecules GmbH, a late-stage clinical biotechnology company focused on the development of differentiated antiviral therapies, today announced that the first patient has been dosed in its Ph ...

Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients ...

New details on the alleged planned attack on the White House during the UFC Freedom 250 event have been revealed after eight ...

If approved, upadacitinib is expected to be the first systemic medication for patients with non-segmental vitiligo, addressing important treatment needs ...

If the US FDA approves it, aglatimagene immunotherapy may become the first new therapy for men with localized prostate cancer in the past 2 decades.